Bicycle Therapeutics plc (BCYC)

From the record

Bicycle Therapeutics plc's filings since 2018 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Bicycle Therapeutics plc's 9 filed years say what it did: revenue went from $2 million in fiscal 2017 to $73 million in fiscal 2025, up 56.1% a year; it rose in 7 of 8 years; the deepest fall was 25% from fiscal 2019 to fiscal 2020; net income was positive in 0 of 9 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bicycle Therapeutics plc lost about 36 cents for every dollar of shareholders' money. Leverage: it owed about 15 cents per dollar of assets, and net share issuance: its share count grew 19.0% over the year (the filed statements).

From the record

Bicycle Therapeutics plc's standing among 315 graded names in its industry family: revenue of $73 million in fiscal 2025 ranks in the top 39% by size; a net margin of -301.7% ranks in the bottom 42%; revenue growth of 71.2% a year over the last 3 filed years ranks in the top 17% (its annual reports).

From the record

Bicycle Therapeutics plc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Lee, Kevin (CHIEF EXECUTIVE OFFICER, as filed), filing under that title since 2019-05-22, 7.5 years (top 27% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 2.7 years (bottom 13%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 48%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bicycle Therapeutics plc's room to grow, from the newest filed statements (fiscal 2025): cash of $629 million against no long-term debt tagged leaves 87.6% of its assets as net cash, top 12% of its family; cash from operations less capital spending is -347.2% of revenue (bottom 39%); research spending of 331% of revenue (top 36%) (its annual report).

From the record

Bicycle Therapeutics plc's growth drivers, from the filed years to fiscal 2025: revenue grew 71.2% a year over the last three filed years against 56.1% over all 9, speeding up (top 17% of its family); the newest year grew 105.9% (top 16%); research spending grew 43.3% a year (top 10%); capital spending grew -50.2% a year (bottom 20%) (its annual reports). Bicycle Therapeutics plc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Bicycle Therapeutics plc's newest year against its own record: revenue of $73 million in fiscal 2025 came in 31.8% above the $55 million its prior three years' pace pointed to (top 23% of its family); net income of $219 million against a prior three-year average of $154 million (bottom 28%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 23%) (its annual reports).